2021 |
02/12 | 15:30 2020年12月期決算短信〔日本基準〕(連結) |
02/12 | 15:30 2020年12月期通期決算説明資料 |
02/08 | 350 | 350 | 339 | 343 | -2% | 209,100 | 100億3312万 | +8.54% |
02/05 | 337 | 350 | 333 | 350 | +5.11% | 239,800 | 102億3788万 | +11.46% |
02/04 | 332 | 336 | 331 | 333 | -0.6% | 56,000 | 97億4061万 | +7.07% |
02/03 | 328 | 338 | 328 | 335 | +0.9% | 123,500 | 97億9911万 | +8.41% |
02/02 | 328 | 332 | 322 | 332 | +1.22% | 48,700 | 97億1136万 | +8.14% |
02/01 | 320 | 328 | 313 | 328 | +1.86% | 80,400 | 95億9436万 | +7.54% |
01/29 | 326 | 333 | 321 | 322 | -2.13% | 125,400 | 94億1885万 | +6.62% |
01/28 | 325 | 331 | 323 | 329 | -0.6% | 73,600 | 96億2361万 | +9.3% |
01/27 | 327 | 333 | 327 | 331 | +0.3% | 71,400 | 96億8211万 | +10.7% |
01/26 | 333 | 335 | 326 | 330 | -1.79% | 124,800 | 96億5286万 | +11.11% |
01/25 | 325 | 336 | 323 | 336 | +3.38% | 197,000 | 98億2836万 | +13.51% |
01/22 | 323 | 325 | 321 | 325 | +0.31% | 83,700 | 95億660万 | +10.54% |
01/21 | 321 | 325 | 320 | 324 | +1.25% | 120,700 | 94億7735万 | +10.58% |
01/20 | 331 | 331 | 318 | 320 | +1.59% | 259,200 | 93億6035万 | +9.59% |
01/20 | 8:45 眼科手術補助剤「DW-1002」のカナダにおける承認取得のお知らせ |
01/19 | 307 | 317 | 306 | 315 | +2.61% | 93,500 | 92億1409万 | +8.25% |
01/18 | 311 | 312 | 300 | 307 | -0.65% | 78,600 | 89億8008万 | +5.5% |
01/15 | 297 | 309 | 297 | 309 | +4.04% | 303,900 | 90億3858万 | +6.55% |
01/14 | 15:30 業績予想の修正に関するお知らせ |
01/14 | 297 | 300 | 296 | 297 | -0.34% | 54,900 | 86億8757万 | +2.41% |
01/13 | 301 | 304 | 298 | 298 | 0% | 79,300 | 87億1682万 | +2.41% |
01/12 | 297 | 301 | 294 | 298 | +1.02% | 158,400 | 87億1682万 | +2.05% |
01/08 | 286 | 296 | 286 | 295 | +2.79% | 105,900 | 86億2907万 | +0.68% |
01/07 | 293 | 293 | 286 | 287 | -1.37% | 71,200 | 83億9506万 | -2.38% |
01/06 | 282 | 292 | 282 | 291 | +3.19% | 103,600 | 85億1207万 | -1.36% |
01/05 | 281 | 286 | 279 | 282 | -1.05% | 95,400 | 82億4881万 | -5.05% |
01/04 | 289 | 289 | 280 | 285 | -1.38% | 118,500 | 83億3656万 | -4.68% |
2020 |
12/30 | 280 | 290 | 280 | 289 | +2.12% | 216,200 | 84億5356万 | -3.99% |
12/29 | 270 | 283 | 269 | 283 | +4.43% | 179,700 | 82億7806万 | -6.29% |
12/28 | 276 | 278 | 268 | 271 | -2.87% | 387,900 | 79億2704万 | -10.86% |
12/25 | 280 | 285 | 278 | 279 | -1.06% | 175,300 | 81億6105万 | -8.82% |
12/24 | 276 | 287 | 275 | 282 | +2.55% | 265,300 | 82億4881万 | -8.44% |
12/23 | 276 | 282 | 275 | 275 | -1.08% | 209,200 | 80億4405万 | -11.29% |
12/22 | 284 | 286 | 278 | 278 | -3.47% | 213,900 | 81億3180万 | -10.9% |
12/21 | 290 | 292 | 285 | 288 | -1.37% | 161,400 | 84億2431万 | -8.28% |
12/18 | 290 | 295 | 286 | 292 | +0.34% | 173,600 | 85億4132万 | -7.3% |
12/17 | 296 | 297 | 290 | 291 | -1.02% | 211,800 | 85億1207万 | -8.2% |
12/16 | 299 | 300 | 292 | 294 | -1.67% | 177,400 | 85億9982万 | -7.55% |
12/15 | 301 | 303 | 298 | 299 | -0.99% | 64,400 | 87億4607万 | -6.27% |
12/14 | 299 | 307 | 297 | 302 | +1.68% | 132,000 | 88億3383万 | -5.63% |
12/11 | 292 | 298 | 292 | 297 | +0.34% | 142,300 | 86億8757万 | -7.48% |
12/10 | 297 | 301 | 296 | 296 | -1.33% | 84,000 | 86億5832万 | -8.07% |
12/09 | 304 | 305 | 295 | 300 | -2.6% | 270,000 | 87億7533万 | -7.41% |
12/08 | 311 | 312 | 303 | 308 | -1.28% | 177,900 | 90億933万 | -4.94% |
12/07 | 320 | 321 | 312 | 312 | -2.19% | 207,200 | 91億2634万 | -4% |
12/04 | 321 | 324 | 318 | 319 | -0.62% | 98,500 | 93億3110万 | -1.85% |
12/03 | 324 | 326 | 320 | 321 | -1.23% | 105,600 | 93億8960万 | -1.53% |
12/02 | 321 | 327 | 321 | 325 | +0.31% | 71,800 | 95億660万 | -0.31% |
12/01 | 324 | 327 | 320 | 324 | -1.22% | 151,800 | 94億7735万 | -0.61% |
11/30 | 15:30 ファシリティ契約に基づく第10回新株予約権(行使価額修正条項付)の行使停止要請通知に関するお知らせ |
11/30 | 331 | 334 | 328 | 328 | -0.91% | 57,000 | 95億9436万 | +0.31% |
11/27 | 327 | 333 | 327 | 331 | +0.61% | 132,600 | 96億8211万 | +1.22% |
11/26 | 331 | 331 | 328 | 329 | 0% | 55,800 | 96億2361万 | +0.61% |
11/25 | 332 | 335 | 327 | 329 | -1.5% | 108,300 | 96億2361万 | +0.3% |
11/24 | 327 | 339 | 326 | 334 | +2.14% | 183,200 | 97億6986万 | +1.83% |
11/20 | 326 | 327 | 323 | 327 | +0.31% | 58,700 | 95億6510万 | -0.61% |
11/19 | 327 | 327 | 321 | 326 | -0.31% | 73,100 | 95億3585万 | -1.21% |
11/18 | 322 | 330 | 320 | 327 | +1.55% | 100,800 | 95億6510万 | -1.21% |
11/17 | 328 | 328 | 321 | 322 | -0.92% | 69,000 | 94億1885万 | -3.01% |
11/16 | 324 | 329 | 322 | 325 | -0.31% | 82,100 | 95億660万 | -2.69% |
11/13 | 321 | 328 | 321 | 326 | -0.61% | 79,800 | 95億3585万 | -2.69% |
11/12 | 15:30 2020年12月期第3四半期決算短信〔日本基準〕(連結) |
11/12 | 326 | 331 | 324 | 328 | +0.31% | 77,900 | 95億9436万 | -2.67% |
11/11 | 323 | 329 | 322 | 327 | +1.24% | 78,500 | 95億6510万 | -3.25% |
11/10 | 328 | 328 | 322 | 323 | -0.62% | 76,100 | 94億4810万 | -4.72% |
11/09 | 331 | 331 | 318 | 325 | +0.62% | 120,300 | 95億660万 | -4.69% |
11/06 | 324 | 330 | 322 | 323 | -0.62% | 93,300 | 94億4810万 | -5.56% |
11/05 | 322 | 329 | 322 | 325 | 0% | 78,200 | 95億660万 | -5.25% |
11/04 | 322 | 329 | 319 | 325 | +2.52% | 130,300 | 95億660万 | -5.52% |
11/02 | 317 | 321 | 313 | 317 | +0.32% | 107,900 | 92億7259万 | -8.12% |
10/30 | 326 | 328 | 315 | 316 | -3.07% | 206,300 | 92億4334万 | -8.93% |
10/29 | 323 | 329 | 321 | 326 | -1.51% | 140,500 | 95億3585万 | -6.32% |
10/28 | 333 | 338 | 326 | 331 | 0% | 101,600 | 96億8211万 | -5.16% |
10/27 | 327 | 335 | 326 | 331 | -0.6% | 153,400 | 96億8211万 | -5.7% |
10/27 | 8:50 神経疼痛治療薬「DW-5LBT」の米国における承認申請受理のお知らせ |
10/26 | 332 | 344 | 332 | 333 | 0% | 123,500 | 97億4061万 | -5.67% |
10/23 | 329 | 334 | 321 | 333 | +1.52% | 164,400 | 97億4061万 | -6.2% |
10/22 | 340 | 340 | 322 | 328 | -3.53% | 324,800 | 95億9436万 | -8.12% |
10/21 | 342 | 344 | 340 | 340 | -0.58% | 120,000 | 90億5083万 | -5.29% |
10/20 | 346 | 349 | 341 | 342 | -1.72% | 135,600 | 91億407万 | -5% |
10/19 | 344 | 351 | 343 | 348 | +0.87% | 70,800 | 92億6379万 | -3.87% |
10/16 | 350 | 352 | 344 | 345 | -1.15% | 141,100 | 91億8393万 | -4.96% |
10/15 | 358 | 358 | 347 | 349 | -3.06% | 279,300 | 92億9041万 | -4.12% |
10/14 | 358 | 364 | 358 | 360 | -0.55% | 90,700 | 95億8323万 | -1.37% |
10/13 | 364 | 364 | 358 | 362 | 0% | 72,500 | 96億3647万 | -0.82% |
10/12 | 362 | 364 | 359 | 362 | +0.28% | 57,300 | 96億3647万 | -1.09% |
10/09 | 357 | 361 | 351 | 361 | +1.12% | 157,600 | 96億985万 | -1.37% |
10/08 | 363 | 363 | 356 | 357 | -0.56% | 87,500 | 95億337万 | -2.72% |
10/07 | 363 | 366 | 356 | 359 | -1.37% | 91,800 | 95億5661万 | -2.45% |
10/06 | 356 | 365 | 355 | 364 | +2.54% | 124,000 | 96億8971万 | -1.09% |
10/05 | 353 | 359 | 350 | 355 | +1.72% | 144,200 | 94億5013万 | -3.53% |
10/02 | 367 | 367 | 348 | 349 | -1.97% | 308,400 | 92億9041万 | -5.68% |
10/01 | 15:30 第10回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ |
10/01 | 15:30 当社子会社(日本革新創薬株式会社)による未熟児網膜症等診断薬に関するライセンス契約締結のお知らせ |
09/30 | 352 | 363 | 352 | 356 | -0.56% | 185,000 | 94億7675万 | -4.04% |
09/29 | 350 | 360 | 348 | 358 | +3.47% | 199,400 | 95億2999万 | -3.5% |
09/28 | 356 | 357 | 343 | 346 | -2.26% | 372,400 | 92億1055万 | -6.99% |
09/25 | 349 | 362 | 347 | 354 | +2.61% | 545,000 | 94億2351万 | -5.35% |
09/24 | 17:55 ファシリティ契約に基づく第10回新株予約権(行使価額修正条項付)の行使停止要請通知に関するお知らせ |
09/24 | 359 | 361 | 345 | 345 | -5.22% | 891,900 | 91億8393万 | -8% |
09/23 | 382 | 384 | 364 | 364 | -2.67% | 2,185,900 | 95億7760万 | -3.19% |
09/18 | 15:30 第10回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ |
09/18 | 459 | 459 | 373 | 374 | -1.32% | 6,811,900 | 98億4072万 | -0.53% |
09/17 | 15:30 米国Glaukos社との共同研究の対象疾患の追加並びに新たなライセンス契約締結のお知らせ |
09/17 | 390 | 390 | 375 | 379 | -2.82% | 102,200 | 99億7228万 | +0.53% |
09/16 | 379 | 392 | 377 | 390 | +2.9% | 158,700 | 102億6171万 | +3.45% |
09/15 | 373 | 381 | 372 | 379 | +1.07% | 77,900 | 99億7228万 | +0.8% |
09/14 | 376 | 379 | 374 | 375 | -0.53% | 55,600 | 98億6703万 | -0.27% |
09/11 | 372 | 379 | 369 | 377 | +0.8% | 88,700 | 99億1966万 | 0% |
09/10 | 372 | 375 | 369 | 374 | -0.27% | 82,500 | 98億4072万 | -0.8% |